J Neuroinflammation: Developed the first targeted antibody therapy that promises to be effective in treating Alzheimer's disease.

September 16, 2020 // -- In a recent study published in the international journal Journal of Neuroinflammation, scientists from the University of Kentucky and other institutions are promising to develop a new treatment for Alzheimer's disease. Using a specific antibody to target inflammatory effects or hopefully treat Alzheimer's disease, which has no effective cure for alzheimer's disease and its associated dementia, has become a public health threat to the health of people around the world as an aging population grows, the researchers said.
photo source: Mark Cornelison. UKphoto's current treatment of Alzheimer's disease focuses on the disease's main pathological markers, amyloid plaques and neurogenic fibrous entanglements, which are necessary to diagnose Alzheimer's disease, however, the researchers say a large amount of genetic data suggests that the risk of extrinsic Alzheimer's disease may be driven by a variety of factors, including neuroinvestment, membrane flipping and size, and lipid metabolism. In the
study, the researchers focused on the trigger receptor (TREM2) expressed in bone marrow cell 2, a gene found a few years ago that significantly increases an individual's risk of developing Alzheimer's disease when it occurs, and the researchers believe that this mutation reduces the function of the receptor, so they hypothesize whether the targeting effect TREM2 increases its function as an effective Alzheimer's therapy.
based on this study, the researchers found that using TREM2 to activate antibodies to therapeutically target the effect of TREM2 may activate small glial cells and recruit small glial cells into amyloid plaques to reduce amyloid plaques Accumulation, which ultimately improves the cognitive abilities of patients, and most importantly, is the first method to target TREM2 to promote the removal of amyloid plaques in the brain, which are thought to be the main cause of Alzheimer's disease.
biopharmaceutical company Aledctor developed this particular antibody in mice, and later researchers will continue to delve into the use of this new method for more clinical trials to confirm its safety.
original source: Brittani R. Price et al Therapeutic Trem2 activation ameliorates amyloid-beta deposition and improves cognition in the 5XFAD model of amyloid deposition, Journal of Neuroinflammation (2020). DOI:10.1186/s12974-020-01915-0.